Corindus Vascular tops revenue expectations for the fourth quarter of 2017 and gears up for tele-stenting trial with Mayo Clinic.
Medtronic continued to strengthen its TAVR story with 5-year-data recently presented at ACC18. The company is battling it out with Edwards in the U.S. market, while Boston Scientific seeks to find footing after delaying commercialization of the Lotus Edge valve.
Strong results from the MOMENTUM 3 clinical trial could help Abbott take a significant part of the destination therapy portion of the LVAD market from Medtronic.
FDA approved a dime-sized mechanical heart valve from Abbott that is the first device of its kind small enough to treat newborns and infants in urgent need of a mitral or aortic valve replacement.
After several acquisitions and divestitures, LivaNova is showing strong momentum exiting the fourth quarter of 2017.
SQI Diagnostics and Predictive Health bring cardiovascular diagnostics to the forefront with the launch of a serum-based heart attack probability test.
Edwards picks up a CE mark for the Centera valve in a move that could strengthen its position in the growing TAVR market.
LivaNova said it will pay up to $250 million for TandemLife, a deal that will significantly bolster its cardiac surgery portfolio.
The organizers of Cardiostim, a meeting focused on electrophysiology and cardiac techniques, have pulled the plug, just months before the event's 40th anniversary was to be held in Nice, France.
Boston Scientific has taken a $90 million stake in Millipede, the developer of a transcatheter annuloplasty ring system, with an option to acquire the remaining shares.
To kick off earnings season, one medtech analyst thinks the cardiovascular, orthopedic, and diagnostic markets grew last quarter, based on early earnings announcements.
Lombard Medical Technologies has defaulted on a loan and said it doesn't have enough cash to survive past the first half of this year. Here's a look at how things went from bad to worse for Lombard.
The transcatheter aortic valve replacement market has already seen rapid growth. But the market leaders say they've only scratched the surface in terms of the growth opportunities in the space.
Angiodynamics updated investors on its lawsuit against C.R. Bard, an effort the company launched last year to level the playing field in the PICC market.
FDA gave MR-conditional labeling to two of Abbott's cardiac rhythm management (CRM) devices, a move that further boosts the company's ability to compete with its peers in the space.